Scientists at Taiwan's Industrial Technology Research Institute have developed a new dual-target medicine they say is more effective and safe in treating glaucoma. The drug is still undergoing clinical trials but could be game-changing for the 430,000 glaucoma patients in Taiwan, and more around the world.